Method
Level · gp.fundamentals.capex_revenue_ratio
Raw value 6.86% · OPTIONAL
· Biological Products, (No Diagnostic Substances)
RESEARCH SNAPSHOTImmunityBio, Inc.'s latest supported as-filed period reports revenue of $51.2M, 93.9% above the comparable as-filed period. Every value below links to its SEC accession and metric lineage.
No material rule-based research observation currently meets GrossPattern's Insight value threshold. Current state, direction, and filing evidence remain available below.
A multidimensional view of the latest comparable filing—not a composite score or recommendation.
Level · gp.fundamentals.capex_revenue_ratio
Raw value 6.86% · OPTIONAL
Ratio · gp.fundamentals.operating_cash_flow + gp.fundamentals.revenue
Raw value -129.77% · OPTIONAL
Yoy · gp.fundamentals.revenue
Raw value 93.91% · CORE
Level · gp.fundamentals.inventory_revenue_ratio
Raw value 3.79% · OPTIONAL
Level · gp.fundamentals.gross_margin
Raw value 99.42% · CORE
Level · gp.fundamentals.operating_margin
Raw value -120.41% · CORE
Level · gp.fundamentals.sbc_revenue_ratio
Business direction, financial quality, capital allocation, and governance evidence remain separate—never collapsed into a recommendation score.
Interpretation boundary Direction describes measurable company fundamentals. Governance reports observable evidence only; it does not grade management character or predict stock returns.
Latest available comparable states within 180 days, normalized with robust median/MAD statistics.
The most important deterministic changes, ranked by magnitude, issuer history, persistence, and accounting profile.
Cash & equivalents changed -45.0% from the comparable as-filed period.
Inventory changed -70.8% from the comparable as-filed period.
Net income changed -148.9% from the comparable as-filed period.
Operating income changed +13.5% from the comparable as-filed period.
Each point keeps the date investors could first observe it and its accession.
IBRX · as filed with the SEC · reported-date aware
Direct SEC links, filing dates, report periods, and amendment flags.
0001326110-26-000079SEC ↗8-KAug 4, 2026Period Aug 4, 20260001326110-26-000077SEC ↗8-KJul 30, 2026Period Jul 29, 20260001326110-26-000071SEC ↗4Jul 6, 2026Period Jul 2, 20260001529371-26-000008SEC ↗4Jul 6, 2026Period Jul 1, 20260001849739-26-000014SEC ↗4Jul 1, 2026Period Jun 29, 20260001849739-26-000011SEC ↗4Jun 26, 2026Period Jun 24, 20260001647994-26-000011SEC ↗Transaction semantics distinguish purchases, sales, awards, exercises, withholding, and derivatives.
| Filed / transacted | Reporting owner | Semantics | Shares | Price | Notional | Source |
|---|---|---|---|---|---|---|
| Jul 2, 2026Filed Jul 6, 2026 | Cohen CherylDirector | Option ExerciseDirect | 55,979 | $3 | $166,817 | Form 4 ↗ |
| Jul 2, 2026Filed Jul 6, 2026 | Cohen CherylDirector | Open Market SaleDirect | 131,210 | $10 | $1.2M | Form 4 ↗ |
| Jul 2, 2026Filed Jul 6, 2026 | Cohen CherylDirector | Option ExerciseDirect | 55,979 | $0 | $0 | Form 4 ↗ |
GrossPattern stores immutable raw artifacts, accession-scoped facts, parser and metric versions, dependency edges, quality state, and channel-specific publication rights. A restricted or unknown ancestor blocks the page and API automatically.
SEC source policy ↗Raw value 16.62% · OPTIONAL
Operating margin changed +14936 basis points from the comparable as-filed period.
Revenue changed +93.9% from the comparable as-filed period.
Stock-based compensation changed -11.7% from the comparable as-filed period.
Method note “Materiality” here is an analytical magnitude band, not a legal conclusion. Full filing-text semantic changes remain unpublished while excerpt rights and review thresholds are unresolved.
Latest supported period in this snapshot: 2026-06-30. Duration facts use direct quarterly or annual SEC contexts; GrossPattern does not manufacture missing Q4 values.
0001371407-26-000003